Life Science Compliance Update

The FDA OPDP issued enforcement letters have been on a steep decline since 2010. This article examines the numbers of OPDP letters…

Increasingly creative methods are being used by big pharma to increase sales. Drug manufacturers are donating billions of dollars…

Handling whistleblowers is one of the biggest challenges facing most compliance officers. Furthermore, recent actions taken by the…

There are some strong indicators to suggest that 2016 is on track to be a real banner year regarding Foreign Corrupt Practices Act…

GlaxoSmithKline (“GSK”) reached a settlement with the Chinese government in 2014 related to bribes and improper actions taken by…

Medicaid Fraud Control Units play an important, if often overlooked, role in the Government’s continuing effort to control…

The SEC’s Office of the Whistleblower recently announced that its whistleblower awards have now exceeded over $100 million…

Value Based Contracts are becoming increasingly important and commonplace. VBCs also have important implications for Government…

The OIG’s recent Advisory Opinion suggest that under certain circumstances patient co-pay reimbursement programs are allowable.…

According to the Ethics & Compliance Initiative (ECI), ethics and compliance programs should not be “check the box programs”…